The vaccine hesitancy continuum among hesitant adopters of the COVID-19 vaccine.

Ramey Moore, Rachel S Purvis, Don E Willis, Kyle C Worley, Devonte Hervey, Sharon Reece, Aimee Yeates, Pearl A McElfish
Author Information
  1. Ramey Moore: College of Medicine, University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, USA. ORCID
  2. Rachel S Purvis: College of Medicine, University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, USA. ORCID
  3. Don E Willis: College of Medicine, University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, USA. ORCID
  4. Kyle C Worley: 4media Group, Bentonville, Arkansas, USA. ORCID
  5. Devonte Hervey: 4media Group, Bentonville, Arkansas, USA.
  6. Sharon Reece: College of Medicine, University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, USA. ORCID
  7. Aimee Yeates: College of Medicine, University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, USA.
  8. Pearl A McElfish: College of Medicine, University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, USA. ORCID

Abstract

Vaccination is a strategy for mitigating the impact of coronavirus disease 2019 (COVID-19) at both the individual and population levels. vaccine hesitancy is identified as a significant threat to global health by the World Health Organization (WHO). vaccine hesitancy has been theorized as a continuum encompassing a range of attitudes, beliefs, emotional orientations, ideologies, and health-seeking behaviors. Individuals who received the COVID-19 vaccine but also indicated some level of hesitancy about vaccination, or "hesitant adopters," remain an understudied group. This study uses a qualitative descriptive design to understand motivations to receive the COVID-19 vaccine among hesitant adopters at various self-reported levels of hesitancy. We conducted interviews with hesitant adopters (n = 49) to analyze the elements of vaccine hesitancy corresponding to reported levels of COVID-19 vaccine hesitancy (i.e., "little hesitant," "somewhat hesitant," and "very hesitant"). Concerns about side effects are shared across the continuum but are articulated differently at each level of hesitancy. The "little hesitant" relate fears of side effects to their health and a lack of clear information to inform their health decision making, whereas the "very hesitant" articulate the risks of side effects within the frame of conspiracies related to the development, approval, and economics of the COVID-19 vaccine. Additionally, conspiracy theories generally increase in salience across the continuum, with the "very hesitant" reporting conspiracy theories as the most salient element of vaccine hesitancy. This research presents opportunities for developing targeted interventions for different levels of vaccine hesitancy.

References

  1. Nat Med. 2022 Mar;28(3):456-459 [PMID: 35273403]
  2. Lancet Reg Health Am. 2022 Mar;7:100203 [PMID: 35187522]
  3. Clin Infect Dis. 2022 Oct 3;75(Supplement_2):S334-S337 [PMID: 35748711]
  4. Vaccine. 2015 Aug 14;33(34):4180-90 [PMID: 25896377]
  5. JMIR Public Health Surveill. 2021 Apr 14;7(4):e26527 [PMID: 33764882]
  6. J Med Virol. 2022 May;94(5):1761-1765 [PMID: 35014038]
  7. Vaccine. 2015 Nov 27;33 Suppl 4:D66-71 [PMID: 26615171]
  8. Int J Environ Res Public Health. 2021 Aug 17;18(16): [PMID: 34444438]
  9. Lancet. 2021 Oct 16;398(10309):1407-1416 [PMID: 34619098]
  10. Nat Hum Behav. 2021 Mar;5(3):337-348 [PMID: 33547453]
  11. Vaccines (Basel). 2021 Dec 01;9(12): [PMID: 34960164]
  12. J Adv Nurs. 1999 Feb;29(2):323-30 [PMID: 10197931]
  13. CMAJ Open. 2019 Aug 20;7(3):E524-E536 [PMID: 31431485]
  14. J Behav Med. 2022 Jan 15;: [PMID: 35032254]
  15. Clin Pract. 2021 Oct 21;11(4):778-784 [PMID: 34698149]
  16. BMJ. 2022 Feb 16;376:o405 [PMID: 35172963]
  17. Qual Health Res. 2005 Nov;15(9):1277-88 [PMID: 16204405]
  18. J Behav Med. 2022 Mar 19;: [PMID: 35305206]
  19. Am J Public Health. 2022 Feb;112(2):234-241 [PMID: 35080944]
  20. Vaccines (Basel). 2021 Mar 22;9(3): [PMID: 33810131]
  21. J Community Health. 2022 Apr;47(2):237-245 [PMID: 34687388]
  22. Glob Health Med. 2021 Dec 31;3(6):413-414 [PMID: 35036625]
  23. JAMA Netw Open. 2021 Sep 1;4(9):e2127582 [PMID: 34591103]
  24. Vaccine. 2022 Apr 14;40(17):2498-2505 [PMID: 34218963]
  25. Am J Public Health. 2022 Feb;112(2):229-231 [PMID: 35080931]
  26. Vaccine. 2015 Aug 14;33(34):4161-4 [PMID: 25896383]
  27. Vaccines (Basel). 2020 Feb 07;8(1): [PMID: 32046228]
  28. Soc Sci Med. 2020 Oct;263:113356 [PMID: 32967786]
  29. Elife. 2021 May 27;10: [PMID: 34042047]
  30. Vaccines (Basel). 2021 Mar 03;9(3): [PMID: 33802285]
  31. J Community Health. 2021 Dec;46(6):1090-1098 [PMID: 33956270]
  32. Vaccines (Basel). 2021 Jun 03;9(6): [PMID: 34204971]
  33. Vaccine. 2021 Jan 29;39(5):825-829 [PMID: 33390295]
  34. Eur J Intern Med. 2021 May;87:106-108 [PMID: 33810941]
  35. Emerg Infect Dis. 2022 May;28(5):1021-1025 [PMID: 35320700]
  36. Mayo Clin Proc. 2021 Mar;96(3):699-707 [PMID: 33673921]
  37. Vaccines (Basel). 2015 Jul 15;3(3):556-78 [PMID: 26350595]
  38. Curr Opin Immunol. 2021 Aug;71:89-91 [PMID: 34271335]
  39. HERD. 2016 Jul;9(4):16-25 [PMID: 26791375]
  40. Vaccine. 2021 Dec 20;39(52):7625-7632 [PMID: 34802786]
  41. Vacunas. 2021 May-Aug;22(2):93-97 [PMID: 33727904]
  42. Expert Rev Vaccines. 2015 Jan;14(1):99-117 [PMID: 25373435]
  43. Vaccine. 2020 Oct 7;38(43):6785-6793 [PMID: 32891475]
  44. Vaccine. 2021 Sep 24;39(40):6004-6012 [PMID: 33160755]
  45. Hum Vaccin Immunother. 2022 Dec 31;18(1):1950504 [PMID: 34325612]
  46. Vaccine. 2019 Feb 21;37(9):1168-1173 [PMID: 30709722]
  47. Acad Pediatr. 2021 May-Jun;21(4S):S9-S16 [PMID: 33958099]
  48. Hum Vaccin Immunother. 2021 Dec 2;17(12):5168-5175 [PMID: 34893018]
  49. Transl Behav Med. 2022 Feb 16;12(2):243-272 [PMID: 34850217]
  50. Vaccines (Basel). 2021 Dec 02;9(12): [PMID: 34960170]
  51. Clin Transl Sci. 2022 Dec;15(12):2844-2857 [PMID: 36330587]
  52. Hum Vaccin Immunother. 2013 Aug;9(8):1763-73 [PMID: 23584253]
  53. Public Health. 2021 May;194:245-251 [PMID: 33965796]
  54. Lancet Public Health. 2021 Apr;6(4):e210-e221 [PMID: 33556325]
  55. Expert Rev Vaccines. 2018 Nov;17(11):989-1004 [PMID: 30359151]
  56. PLoS Curr. 2016 Dec 29;8: [PMID: 28239512]

Grants

  1. R01 MD013852/NIMHD NIH HHS
  2. UL1 TR003107/NCATS NIH HHS
  3. OT2 HL156812/NHLBI NIH HHS
  4. NIH 10T2HL156812-01/NIH HHS
  5. NIH 3 R01MD013852-02S3/NIH HHS
  6. NIH 3 R01MD013852-03S2/NIH HHS
  7. P20 GM103429/NIGMS NIH HHS

MeSH Term

Humans
COVID-19 Vaccines
Vaccination Hesitancy
COVID-19
Drug-Related Side Effects and Adverse Reactions
World Health Organization
Vaccination

Chemicals

COVID-19 Vaccines

Word Cloud

Created with Highcharts 10.0.0hesitancyvaccineCOVID-19hesitantlevelscontinuumadoptershesitant"health""verysideeffectsVaccinelevelamong"littleacrossconspiracytheoriesVaccinationstrategymitigatingimpactcoronavirusdisease2019individualpopulationidentifiedsignificantthreatglobalWorldHealthOrganizationWHOtheorizedencompassingrangeattitudesbeliefsemotionalorientationsideologieshealth-seekingbehaviorsIndividualsreceivedalsoindicatedvaccination"hesitantremainunderstudiedgroupstudyusesqualitativedescriptivedesignunderstandmotivationsreceivevariousself-reportedconductedinterviewsn = 49analyzeelementscorrespondingreportedie"somewhatConcernssharedarticulateddifferentlyrelatefearslackclearinformationinformdecisionmakingwhereasarticulateriskswithinframeconspiraciesrelateddevelopmentapprovaleconomicsAdditionallygenerallyincreasesaliencereportingsalientelementresearchpresentsopportunitiesdevelopingtargetedinterventionsdifferent

Similar Articles

Cited By (16)